PT91236A - Metodo para a purificacao de activadores do pasminogeneo de glandulas salivares de morcegos vampiros - Google Patents

Metodo para a purificacao de activadores do pasminogeneo de glandulas salivares de morcegos vampiros

Info

Publication number
PT91236A
PT91236A PT91236A PT9123689A PT91236A PT 91236 A PT91236 A PT 91236A PT 91236 A PT91236 A PT 91236A PT 9123689 A PT9123689 A PT 9123689A PT 91236 A PT91236 A PT 91236A
Authority
PT
Portugal
Prior art keywords
activators
vampiros
salivares
pasminogeneous
glandulas
Prior art date
Application number
PT91236A
Other languages
English (en)
Other versions
PT91236B (pt
Inventor
George E Mark Iii
John A Friedman
Le Thi Duong
Stephen J Gardell
John W Jacobs
Richard A F Dixon
Bruce L Daugherty
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT91236A publication Critical patent/PT91236A/pt
Publication of PT91236B publication Critical patent/PT91236B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT91236A 1988-07-20 1989-07-20 Metodo para a purificacao de activadores do pasminogeneo de glandulas salivares de morcegos vampiros PT91236B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22169788A 1988-07-20 1988-07-20
US37722189A 1989-07-13 1989-07-13

Publications (2)

Publication Number Publication Date
PT91236A true PT91236A (pt) 1990-02-08
PT91236B PT91236B (pt) 1995-03-01

Family

ID=26916041

Family Applications (1)

Application Number Title Priority Date Filing Date
PT91236A PT91236B (pt) 1988-07-20 1989-07-20 Metodo para a purificacao de activadores do pasminogeneo de glandulas salivares de morcegos vampiros

Country Status (17)

Country Link
US (1) US5830849A (pt)
EP (1) EP0352119B1 (pt)
JP (1) JP2713467B2 (pt)
KR (1) KR0138997B1 (pt)
AT (1) ATE126269T1 (pt)
AU (1) AU621389B2 (pt)
CA (1) CA1341090C (pt)
DE (1) DE68923741T2 (pt)
DK (1) DK176140B1 (pt)
ES (1) ES2076965T3 (pt)
FI (1) FI100403B (pt)
GR (1) GR3017587T3 (pt)
IE (1) IE69054B1 (pt)
IL (1) IL91059A (pt)
NO (2) NO302954B1 (pt)
NZ (1) NZ230017A (pt)
PT (1) PT91236B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500322A (ja) * 1986-03-28 1989-02-09 クリエイティブ　バイオモレクレス，インコーポレーテッド 組織プラスミノーゲンアクテイベーター類縁蛋白質
US6008019A (en) * 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
ES2085326T3 (es) * 1989-02-13 1996-06-01 Schering Ag Activador de plasminogeno salivar del murcielago vampiro vpa-alfa1.
DE3943241A1 (de) * 1989-12-22 1991-06-27 Schering Ag Thrombolytisch wirkendes kombinationspraeparat
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
JPH06506459A (ja) * 1991-04-16 1994-07-21 ロシュ ダイアグノスティックス ゲーエムベーハー プラスミノーゲン活性化剤を含有する多重ボーラス投与用医薬パッケージユニット
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
AU2003227721A1 (en) * 2003-05-02 2004-11-23 Paion Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
EP1622639B1 (de) * 2003-05-02 2013-01-16 Lundbeck, H., A/S Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
EP2289541A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders
EP2289542A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders
TWI866194B (zh) 2017-02-03 2024-12-11 法商艾提寇生物技術公司 使用抗人類ｇｐｖｉ抗體抑制血小板凝集
EP3624832B1 (en) 2017-05-16 2025-08-20 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
EP3806833A1 (en) 2018-06-15 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
BR112021015431A2 (pt) * 2019-02-05 2021-10-05 Dyno Nobel Asia Pacific Pty Limited Grânulos de nitrato de amônio estabilizado por fase e produtos e métodos relacionados
WO2021148439A1 (en) 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stimulating cerebrovascular function
EP4161579A1 (en) 2020-06-09 2023-04-12 Institut National de la Santé et de la Recherche Médicale (INSERM) Fucoidan-functionalized polysaccharide particles with t-pa for targeted thrombolytic therapy
WO2023156683A1 (en) 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies
EP4556492A1 (en) 2023-11-14 2025-05-21 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies in subpopulations of subjects

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5010002A (en) * 1983-01-19 1991-04-23 Genentech, Inc. Human t-PA production using vectors coding DHFR protein
ATE90967T1 (de) * 1986-03-28 1993-07-15 Creative Biomolecules Inc Proteinanaloge des gewebs-plasminogenaktivators.
AU605364B2 (en) * 1987-10-09 1991-01-10 Monsanto Company Modified tissue plasminogen activator
ES2085326T3 (es) * 1989-02-13 1996-06-01 Schering Ag Activador de plasminogeno salivar del murcielago vampiro vpa-alfa1.

Also Published As

Publication number Publication date
NO302954B1 (no) 1998-05-11
JP2713467B2 (ja) 1998-02-16
FI893500L (fi) 1990-01-21
IE892354L (en) 1990-01-20
FI893500A0 (fi) 1989-07-19
EP0352119A3 (en) 1990-07-04
AU3891589A (en) 1990-01-25
US5830849A (en) 1998-11-03
ES2076965T3 (es) 1995-11-16
PT91236B (pt) 1995-03-01
NO970603L (no) 1990-01-22
FI100403B (fi) 1997-11-28
EP0352119A2 (en) 1990-01-24
NO892976D0 (no) 1989-07-20
DK357589D0 (da) 1989-07-19
DK357589A (da) 1990-01-23
CA1341090C (en) 2000-08-29
IE69054B1 (en) 1996-08-07
NO970603D0 (no) 1997-02-10
NZ230017A (en) 1992-05-26
NO314548B1 (no) 2003-04-07
DE68923741T2 (de) 1996-02-15
DE68923741D1 (de) 1995-09-14
IL91059A (en) 1995-06-29
KR0138997B1 (ko) 1998-04-30
GR3017587T3 (en) 1995-12-31
EP0352119B1 (en) 1995-08-09
JPH02167075A (ja) 1990-06-27
AU621389B2 (en) 1992-03-12
KR910003094A (ko) 1991-02-26
DK176140B1 (da) 2006-09-25
ATE126269T1 (de) 1995-08-15
IL91059A0 (en) 1990-02-09
NO892976L (no) 1990-01-22

Similar Documents

Publication Publication Date Title
PT91236A (pt) Metodo para a purificacao de activadores do pasminogeneo de glandulas salivares de morcegos vampiros
ES8802537A1 (es) Un procedimiento para preparar una celula huesped con un vector de expresion correspondiente a un activante de plasminogenos de tipo tejido modificado.
ES2018729A6 (es) Un metodo para preparar una variante de activador de plasmogeno de tejido.
HUT77431A (hu) Fonálféregből kivont szerinproteáz-inhibitorok és véralvadásgátló proteinek
AU5617786A (en) Expression of factor vii and ix activities in mammalian cells
DK0698105T3 (da) Nukleotidsekvenser til styring af ekspressionen af DNAsekvenser i en værtscelle
BR9916347A (pt) Enzima de subtilase, subtilase, sequência isolada de dna, vetor de expressão, célula hospedeira microbiana, método para produzir uma subtilase ou uma variante de subtilase, composição, e, uso de uma subtilase ou de uma variante de subtilase
AU6683086A (en) Novel peptide plasminogen activators
EP0714435A4 (en) PRO-UROKINASE MUTANTS
ATE79273T1 (de) Stabilisierte zusammensetzungen von menschlichen aktivatoren des gewebeplasminogens.
AU2002314738A1 (en) Methods for the production of products in host cells
CA2035900A1 (fr) Proteine a activite urate oxydase, gene recombinant codant pour celle-ci, vecteur d'expression, micro-organismes et cellules transformees
NZ242124A (en) Dna encoding an enzyme having arabinan-degrading activity
WO1988005081A3 (en) Novel plasminogen activator
AU5015696A (en) Plant promoter and method for gene expression using said promoter
WO1994001128B1 (en) Enhancement of thrombolytic therapy with deglycosylated plasminogen
ES2079442T3 (es) Oxidacion enzimatica mejorada de cef c a acido glutaril-7-amino-cefalosporanico.
DK203588D0 (da) Fremgangsmaade til fremstilling af proteiner
DK0444775T3 (da) Rekombinant-DNA-ekspressionsvektorer og DNA-forbindelser, som koder for isopenicillin-N-epimerase-ak tivitet
FI932196A0 (fi) Foerfarande foer bestaemning av fibrinogen
EP0381331A3 (en) Gene sequences encoding modified residues situated in the protease domain of tpa
DE3879534D1 (de) Genetische kontrolleinheit und klonierungs- und expressionssystem.
AU1200388A (en) A method for the functional determination of protein c inhibitor
AU6363486A (en) Promoter arrangement for streptomycetes vectors
BR9916348A (pt) Enzima de subtilase, subtilase, sequência isolada de dna, vetor de expressão, célula hospedeira microbiana, método para produzir uma subtilase ou uma variante de subtilase, composição, e, uso de uma subtilase ou de uma variante de subtilase

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19940817

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20090817